# Reset Therapeutic

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/reset-therapeutic

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.resettherapeutics.com
- Total disclosed funding: $30M
- Latest round: Series B (Feb 18, 2016)
- Investors on record: 1

## About

Reset Therapeutics specializes in developing therapeutic solutions aimed at addressing specific health challenges. The company leverages innovative approaches to enhance treatment efficacy and improve patient outcomes.Reset Therapeutics, founded in 2008, is based in San Francisco, US. The company focuses on developing novel therapeutic solutions and has completed 5 deals to date. In February 2016, they raised USD 29.73 mn in Series B funding from Bay City Capital, bringing the total amount raised to USD 29.73 mn and valuing the company at USD 71.90 mn. The founder's history is not disclosed, and there is no mention of any company pivots or subsidiaries.Reset Therapeutics offers innovative therapeutic solutions that target specific health conditions, enhancing treatment effectiveness. The company serves various sectors within the healthcare industry, focusing on personalized medicine. Their products are designed to meet regulatory requirements in diverse geographical markets, ensuring compliance while catering to the unique needs of their clients.The revenue model of Reset Therapeutics is based on strategic partnerships and direct client transactions. Their business transactions include subscription-based services, where clients engage in long-term contracts for ongoing support and updates. Additionally, the company generates revenue through direct-to-consumer sales of flagship products, accommodating a range of customer needs from enterprise solutions to individual offerings.Reset Therapeutics plans to utilize the proceeds from the Series B funding raised in February 2016 to support the development of new therapeutic products aimed at enhancing patient care. They are targeting expansion into additional markets within North America and Europe by 2024 to broaden their reach. The funding will also facilitate the launch of these upcoming products, supporting the company’s strategy to address unmet medical needs.

## Funding rounds

- Series B, Feb 18, 2016, $30M — Bay City Capital

## Investors

- Bay City Capital (https://capitalatlas.ai/funds/bay-city-capital) — Series B